The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis
- PMID: 28364865
- DOI: 10.1016/j.maturitas.2017.02.009
The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis
Abstract
Objective: Data on the effect of hormone replacement therapy (HRT) and tibolone on lipoprotein (a) [Lp(a)], an independent risk factor for cardiovascular disease, are heterogeneous and conflicting. Studies of the effect of HRT and tibolone on Lp(a) concentrations in post-menopausal women are reviewed in this meta-analysis.
Design and methods: MEDLINE, Scopus, EMBASE and Cochrane databases were searched (up to February 10, 2017). Two researchers identified randomized controlled studies and extracted data. Potential controversies were resolved by a third reviewer.
Results: In 24 eligible studies, HRT caused a significant reduction in Lp(a) concentrations compared with placebo or no treatment [mean relative difference: -20.35%, 95% Confidence Interval (CI): -25.33% to -15.37%, p<0.0001], with significant heterogeneity between studies (I2=98.5%), but without evidence of publication bias. No significant effect was found for tibolone (n=7) (mean relative difference: -23.84%, 95% CI: -63.43% to 15.74%, p=0.238) (I2=98.7%, but without publication bias). Oral estrogen caused a greater reduction in Lp(a) concentrations than transdermal estrogen (n=10) (mean relative difference: 37.66%, 95% CI: 16.84% to 58.48%, p<0.0001), with significant heterogeneity between studies (I2=99%), but no evidence of publication bias. No difference was observed when continuous was compared with cyclical HRT, conventional with low-dose estrogen, and estrogen monotherapy with estrogen combined with progestogen. No difference was observed between HRT and tibolone regarding their effect on Lp(a).
Conclusions: HRT significantly decreases Lp(a) concentrations, with oral being more effective than transdermal estradiol. The type of HRT, dose of estrogen and addition of progestogen do not seem to modify the Lp(a)-lowering effect of HRT.
Keywords: Cardiovascular risk; Lipoprotein (a); Menopause; Meta-analysis; Postmenopausal women.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution.Cochrane Database Syst Rev. 2000;(2):CD001018. doi: 10.1002/14651858.CD001018. Cochrane Database Syst Rev. 2000. PMID: 10796730
-
Long-term hormone therapy for perimenopausal and postmenopausal women.Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5. Cochrane Database Syst Rev. 2017. PMID: 28093732 Free PMC article.
-
Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients.Atherosclerosis. 2015 Sep;242(1):87-96. doi: 10.1016/j.atherosclerosis.2015.06.056. Epub 2015 Jul 2. Atherosclerosis. 2015. PMID: 26186655
-
Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome.Cochrane Database Syst Rev. 2017 Mar 3;3(3):CD010503. doi: 10.1002/14651858.CD010503.pub2. Cochrane Database Syst Rev. 2017. PMID: 28257559 Free PMC article.
-
Hormone replacement therapy for cognitive function in postmenopausal women.Cochrane Database Syst Rev. 2002;(3):CD003122. doi: 10.1002/14651858.CD003122. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003122. doi: 10.1002/14651858.CD003122.pub2. PMID: 12137675 Updated.
Cited by
-
Lipoprotein(a) plasma levels, bone mineral density and risk of hip fracture: a post hoc analysis of the Women's Health Initiative, USA.BMJ Open. 2019 Apr 24;9(4):e027257. doi: 10.1136/bmjopen-2018-027257. BMJ Open. 2019. PMID: 31023762 Free PMC article. Clinical Trial.
-
Non-genetic influences on lipoprotein(a) concentrations.Atherosclerosis. 2022 May;349:53-62. doi: 10.1016/j.atherosclerosis.2022.04.006. Atherosclerosis. 2022. PMID: 35606076 Free PMC article. Review.
-
Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a).Int J Mol Sci. 2023 Sep 3;24(17):13622. doi: 10.3390/ijms241713622. Int J Mol Sci. 2023. PMID: 37686428 Free PMC article. Review.
-
Lipoprotein Metabolism, Dyslipidemia, and Lipid-Lowering Therapy in Women: A Comprehensive Review.Pharmaceuticals (Basel). 2024 Jul 9;17(7):913. doi: 10.3390/ph17070913. Pharmaceuticals (Basel). 2024. PMID: 39065763 Free PMC article. Review.
-
Lipoprotein(a) and cardiovascular disease.Biochem J. 2024 Oct 2;481(19):1277-1296. doi: 10.1042/BCJ20240037. Biochem J. 2024. PMID: 39302109 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous